First Eagle Investment Management LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) during the third quarter, Holdings Channel reports. The fund bought 725,755 shares of the company’s stock, valued at approximately $50,679,000.
Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Cullen Capital Management LLC lifted its holdings in Zoetis by 1.2% in the third quarter. Cullen Capital Management LLC now owns 11,284 shares of the company’s stock valued at $788,000 after acquiring an additional 132 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Zoetis during the third quarter worth $1,323,000. SBI Okasan Asset Management Co.Ltd. acquired a new stake in Zoetis during the third quarter worth $633,000. Teachers Retirement System of The State of Kentucky raised its position in Zoetis by 4.8% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 95,713 shares of the company’s stock valued at $6,683,000 after purchasing an additional 4,375 shares during the period. Finally, Minneapolis Portfolio Management Group LLC raised its position in Zoetis by 233.3% in the third quarter. Minneapolis Portfolio Management Group LLC now owns 303,853 shares of the company’s stock valued at $21,218,000 after purchasing an additional 212,691 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the company. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research note on Tuesday, August 25th. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. The Goldman Sachs Group began coverage on shares of Zoetis in a report on Friday, October 16th. They issued a “neutral” rating and a $74.00 price objective on the stock. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Finally, TD Cowen dropped their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Eight investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $101.25.
Read Our Latest Report on Zoetis
Zoetis Stock Down 1.3%
Shares of NYSE ZTS opened at $83.32 on Wednesday. The firm has a market cap of $33.85 billion, a price-to-earnings ratio of 14.17, a PEG ratio of 1.22 and a beta of 0.67. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49. The business’s 50 day moving average is $76.64 and its two-hundred day moving average is $91.18.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the business posted $1.70 earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. Research analysts predict that Zoetis Inc. will post 6.29 EPS for the current year.
Zoetis Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis’s payout ratio is currently 36.05%.
Zoetis Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
